ReviewFrontiers in immunology2025
Recent progress in pig-to-human kidney xenotransplantation.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Research Progress and Critical Challenges of Bioartificial Kidneys in Renal Replacement Therapy for End-Stage Renal Disease.Biomolecules · 2026Review
- Pig Matrix: a matched multiomics 3D regulatory genomics database for evolutionary and comparative analyses in pigs.Molecular biology and evolution · 2026Article
- Porcine xenotransplantation in the clinical era: converging advances and unresolved barriers on the path to clinical translation - a narrative review.Frontiers in immunology · 2026Review
- T cell-mediated immune responses in xenotransplantation: mechanisms and therapeutic strategies.Frontiers in immunology · 2026Review
- The integration of psychosocial care, ethical governance, and patient-centered research in current and future approaches in the field of vascularized composite allotransplantation.Frontiers in transplantation · 2026Review
- Xenoperfusion-The Transformative Role of Machine Perfusion in Xenotransplantation.XenotransplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even though the patient kept up his dialysis regimen as he had before xenotransplantation, this is a significant development for xenotransplantation. This benchmark for xenotransplantation has the following significant findings. Firstly, from the patient's perspective, the patient was able to regain energy and quality of life and experience normal metabolic filtration (creatinine clearance) during the functional period, thanks to the transplant, which significantly reduced his need for dialysis. Secondly, this is a historic accomplishment for xenotransplantation because it set up a new global record for xenotransplantation survival that exceeds all prior attempts. Thirdly, it brings hope for solving the problem of worldwide organ shortage. Lastly, the FDA has authorized more extensive clinical trials that may include more than thirty patients from several transplant facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.